Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Co.'s primary product candidates include: CYAD-101, which is an investigational, non-gene edited, allogeneic CAR T candidate engineered to co-express a CAR based on natural killer group 2D ligands, a receptor expressed on natural killer cells that binds to eight stress-induced ligands and T cell receptor inhibitory molecule; and CYAD-211, which is an investigational, short hairpin RNA-based allogeneic CAR T candidate for the treatment of relapsed / refractory multiple myeloma. The CYAD stock yearly return is shown above.
The yearly return on the CYAD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYAD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|